## Edgar Filing: PDL BIOPHARMA, INC. - Form DEFA14A

PDL BIOPHARMA, INC. Form DEFA14A April 30, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**SCHEDULE 14A** 

Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934

Filed by the Registrant þ

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement Confidential, for Use of the Commission Only Definitive Proxy Statement (as permitted by Rule 14a-6(e)(2))

**b**Definitive Additional Materials

Soliciting Material Pursuant to 240.14a-12

PDL BIOPHARMA, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing proxy statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

bNo fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.


- (1) Title of each class of securities to which transaction applies:
- (2) Aggregate number of securities to which transaction applies:
- Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
- (4) Proposed maximum aggregate value of transaction:
- (5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

- (1) Amount Previously Paid:
- (2) Form, Schedule or Registration Statement No.:
- (3) Filing Party:

(4) Date Filed:



Edgar Filing: PDL BIOPHARMA, INC. - Form DEFA14A

## Edgar Filing: PDL BIOPHARMA, INC. - Form DEFA14A